Last reviewed · How we verify
PLASMA DERIVED Factor VIII
At a glance
| Generic name | PLASMA DERIVED Factor VIII |
|---|---|
| Also known as | ALPHANATE |
| Sponsor | Fondazione Angelo Bianchi Bonomi |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age (PHASE3)
- Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate
- Fibrinogen in Liver Transplant (PHASE4)
- Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
- Fibrinogen in Liver Transplant Subjects (PHASE4)
- Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A (PHASE4)
- Type 3 Von Willebrand International Registries Inhibitor Prospective Study
- A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLASMA DERIVED Factor VIII CI brief — competitive landscape report
- PLASMA DERIVED Factor VIII updates RSS · CI watch RSS
- Fondazione Angelo Bianchi Bonomi portfolio CI